Table 3 Pharmacokinetic parameters (mean ± SD) of laquinimod in MS patients following repeated daily administration for 21 days
From: Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Dose (mg) | n | t max a (h) | C max (ng/mL) | C min (ng/mL) | AUC0–24 (ng h/mL) | Dose -normalized | |
|---|---|---|---|---|---|---|---|
C max | AUC0–24h | ||||||
0.9 | 10 | 0.99 (0.25–2.00) | 639.6 ± 114.9 | 469.5 ± 103.4 | 12,245.8 ± 2075.4 | 710.6 ± 127.6 | 13,606.5 ± 2306.0 |
1.2 | 12 | 0.75 (0.25–4.00) | 779.2 ± 115.7 | 565.7 ± 121.0 | 15,075.2 ± 2757.6 | 649.4 ± 96.4 | 12,562.7 ± 2298.0 |
1.5 | 12 | 1.00 (0.50–24.00) | 1207.8 ± 210.8 | 904.0 ± 189.5 | 22,974.0 ± 3756.6 | 805.2 ± 140.6 | 15,316.0 ± 2504.4 |
1.8 | 11 | 0.50 (0.25–3.00) | 1449.4 ± 325.4 | 1076.7 ± 274.3 | 28,042.7 ± 6495.5 | 805.2 ± 180.8 | 15,579.3 ± 3608.6 |
2.1 | 11 | 2.00 (0.50–6.00) | 1712.1 ± 385.8 | 1310.5 ± 356.0 | 33,741.2 ± 8133.4 | 815.3 ± 183.7 | 16,067.2 ± 3873.1 |
2.4 | 10 | 0.50 (0.50–2.00) | 1892.3 ± 526.3 | 1389.3 ± 512.9 | 35,470.0 ± 11,100.2 | 788.5 ± 219.3 | 14,779.2 ± 4625.1 |
2.7 | 10 | 1.00 (0.5–2.00) | 1826.2 ± 313.4 | 1364.5 ± 186.7 | 35,274.5 ± 5973.0 | 676.4 ± 116.1 | 13,064.6 ± 2212.2 |